Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717533 · ClinicalTrials.gov registry record
Blood Volume Analysis and Renal Outcomes in Hemodialysis
A clinical trial of Kidney Failure and End Stage Renal Failure on Dialysis, sponsored by VA New York Harbor Healthcare System.
- Completed
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT02717533 is a study of Kidney Failure and End Stage Renal Failure on Dialysis that has completed, run by VA New York Harbor Healthcare System. The registered enrollment target is 12 participants, below the 587-participant average among 18 other Kidney Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02717533, a study of Kidney Failure and End Stage Renal Failure on Dialysis, has completed, sponsored by VA New York Harbor Healthcare System.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the proposed study is to demonstrate that serial blood volume analysis (BVA) using RI-BVA (BVA-100, Daxor, NY) can be used to guide changes in prescription of dry weight for hemodialysis patients. The knowledge of a patient's ideal BV and degree of hypervolemia using these measurements can be used to change the prescription of DW in an objective way instead of the current standard of practice, which is based on subjective prescription of dry weight. A first study was conducted to determine the rate of plasma volume (PV) re-expansion for each patient as a guide to rate of fluid removal (results published, refer to citations). A second study was conducted in order to assess the value of a BVA measurement in guiding prescription of clinical DW. A follow up BVA would then be done in order to check if patients were closer to ideal BV than prior to changing dry weight.
Conditions Studied
Interventions
- OTHER dry weight adjustment
Study Locations (1)
New York
- New York Harbor VA Healthcare System Hemodialysis Unit - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02717533
The ClinicalTrials.gov registry entry for NCT02717533 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 587-participant average among 18 other Kidney Failure trials with a reported enrollment target (98% lower). The listed sponsor is VA New York Harbor Healthcare System, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Failure appearing as the primary indexed condition, and to 1 intervention - of which dry weight adjustment is the first listed.
NCT02717533 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02717533 about?
NCT02717533 is a clinical study titled "Blood Volume Analysis and Renal Outcomes in Hemodialysis". The objective of the proposed study is to demonstrate that serial blood volume analysis (BVA) using RI-BVA (BVA-100, Daxor, NY) can be used to guide changes in prescription of dry weight for hemodialysis patients. The knowledge of a patient's ideal BV and degree of hypervolemia using these measureme...
What is the current status of trial NCT02717533?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2014-01. Estimated completion is 2015-01.
What conditions does trial NCT02717533 study?
This clinical trial studies the following conditions: Kidney Failure, End Stage Renal Failure on Dialysis, Actual Impaired Fluid Volume.
What interventions are being tested in trial NCT02717533?
The interventions under investigation include: dry weight adjustment (OTHER).
Who is sponsoring clinical trial NCT02717533?
This trial is sponsored by VA New York Harbor Healthcare System, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02717533 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerance Through Mixed Chimerism (Sip-Tego)
RECRUITING · Early Phase 1
-
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
RECRUITING · Phase 1
-
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
RECRUITING
-
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
RECRUITING · NA
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.